Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
- 595 Downloads
In 2011, the Spanish Society of Medical Oncology and the Spanish Society of Pathology started a joint project to establish recommendations on biomarker testing in patients with advanced non-small-cell lung cancer based on the current evidence. Most of these recommendations are still valid, but new evidence requires some aspects to be updated. Specifically, the recommendation about which biomarkers to test in which patients is being amended, and the best way to manage tumour samples and minimum requirements for biomarker test material are defined. Suitable techniques for testing for epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement are also reviewed, and a consensus is reached on which situations warrant re-biopsy.
KeywordsALK Biomarkers EGFR Lung cancer
The authors are grateful for the editorial assistance of Ana Martín of HealthCo (Madrid, Spain) in the production of this manuscript. F. López-Ríos thanks B. Angulo and E. Conde for their contribution to lung carcinoma targeted therapies. SEOM and SEAP are grateful for financial support for this project in the form of unrestricted grants from AstraZeneca, Boehringer Ingelheim, Lilly, Novartis, Pfizer and Roche.
Conflict of interest
The authors declare that, when writing and revising the text, they did not know the names of the pharmaceutical companies that provided financial support for this project, so this support has not influenced the content of this article.
- 1.Garrido P, de Castro J, Concha A, Felip E, Isla D, Lopez-Rios F, et al. Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin Transl Oncol. 2012;14:338–49.PubMedCrossRefGoogle Scholar
- 4.Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46.PubMedCrossRefGoogle Scholar
- 7.Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S et al. 2nd ESMO Consensus Conference on Lung Cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol. 2014;25(9):1681–90. doi: 10.1093/annonc/mdu145.
- 9.Fan L, Feng Y, Wan H, Shi G, Niu W (2014) Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis. Available at http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0100866. Accessed July 2014. PLoS One.
- 10.Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba, II et al (2014) Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998–2006.Google Scholar
- 12.Mok T, Kim D-W, Wu Y-L, Solomon BJ, Nakagawa K, Mekhail T et al (2014) (First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). J Clin Oncol 32: 5s (suppl; abstr 8002).Google Scholar
- 14.Kim D-W, Mehra R, Tan DS-W, Felip E, Chow LQM, Camidge DR, et al. Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): results of the ASCEND-1 trial. ASCO Meet Abstr. 2014;32:8003.Google Scholar
- 17.Lopez-Rios F, Conde E, Angulo B, Martinez R, McGready C, O’Hara G, et al. A prospective protocol for simultaneous genomic testing in patients with non-small cell lung cancer. J Thorac Oncol. 2013;8:S1074.Google Scholar
- 18.EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer. NICE diagnostics guidance 9. Available at http://guidance.nice.org.uk/nicemedia/live/14251/64893/64893.pdf. Accessed May 2014.
- 19.Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013;137:828–60.PubMedCentralPubMedCrossRefGoogle Scholar
- 22.Hutarew G, Hauser-Kronberger C, Strasser F, Llenos IC, Dietze O. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH. Histopathology. 2014;65(3):398–407. doi: 10.1111/his.12399.
- 23.FDA clears BioView Duet™ system for automated ALK FISH scanning of lung cancer tissue specimens. Available at http://www.bioview.co.il/htmls/page_70.aspx?c0=12677&bsp=12624. Accessed June 2014.
- 28.Wynes MW, Sholl LM, Dietel M, Schuuring E, Tsao MS, Yatabe Y, et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol. 2014;9:631–8.PubMedCentralPubMedGoogle Scholar
- 29.Zwaenepoel K, Van Dongen A, Lambin S, Weyn C, Pauwels P. Detection of ALK expression in NSCLC with ALK-gene rearrangements: comparison of multiple IHC methods. Histopathology. 2014. doi: 10.1111/his.12414.
- 31.Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, Rusch VW, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008;32:810–27.PubMedCrossRefGoogle Scholar
- 32.Arcila ME, Oxnard GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res. 2011;17:1169–80.PubMedCentralPubMedCrossRefGoogle Scholar
- 33.Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Nanjo S, et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negative populations. Cancer. 2013;119:4325–32.PubMedCrossRefGoogle Scholar
- 34.Janne PA, Ramalingam SS, Yang JC-H, Ahn M-J, Kim D-W, Kim S-W, et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). ASCO Meet Abstr. 2014;32:8009.Google Scholar
- 35.Sequist LV, Soria J-C, Gadgeel SM, Wakelee HA, Camidge DR, Varga A, et al. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). ASCO Meet Abstr. 2014;32:8010.Google Scholar
- 41.Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R et al. Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer. N Engl J Med. 2014 [Epub ahead of print].Google Scholar
- 45.The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543–50.Google Scholar
- 47.Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med. 2013;137:668–84.PubMedCrossRefGoogle Scholar